Incretin-based Drugs Market Size & Share 2026-2035

Incretin-based Drugs Market Size

The global incretin-based drugs market was valued at USD 39.4 billion in 2025, and is projected to rise from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, at a 6.4% CAGR .

GLP-1 receptor agonists generated USD 25.7 billion, or 65.1% of 2025 revenue. North America accounted for 45.7% of revenue, Europe generated USD 8.1 billion, and Asia Pacific held 22.6% and is forecast to expand at about 6.7% .

Incretin-based therapies comprise GLP-1 receptor agonists and DPP-4 inhibitors, which enhance glucose-dependent insulin activity through different pharmacological routes. GLP-1 agents directly activate the receptor, while DPP-4 inhibitors prolong endogenous incretin activity. Tirzepatide adds GIP-receptor activity to GLP-1 agonism, a distinction reflected in its glycemic and weight-loss trial results , ^{[1]Springer Nature, *Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects*. link.springer.com}.

The revenue outlook depends less on incretin biology alone than on the widening clinical role of the class. ADA treatment guidance gives GLP-1 receptor agonists and dual GIP/GLP-1 agonists a central role where glycemic, weight, cardiovascular, kidney, or heart-failure considerations shape treatment selection ^{[2]American Diabetes Association, *Pharmacologic Approaches to Glycemic Treatment, Standards of Care in Diabetes*. diabetesjournals.org}. This creates demand beyond conventional glucose escalation, although reimbursement and tolerability determine how much of the clinically eligible population converts to sustained treatment.

Key Drivers

Rising Prevalence of Type 2 Diabetes Mellitus

Diabetes prevalence provides the durable demand base for both drug classes. WHO reports that the number of people living with diabetes rose from 200 million in 1990 to 830 million in 2022, and that more than 95% have type 2 diabetes ^{[5]World Health Organization, *Diabetes*. who.int}. The increase is particularly consequential in lower- and middle-income settings, where treatment gaps remain substantial: WHO reported that 450 million adults aged 30 years and older with diabetes were not receiving medication in 2022 .

The demand effect is conditional on diagnosis, affordability, and treatment capacity. As those systems improve, incretins can displace or complement older escalation regimens, especially where guideline-based use recognizes cardiovascular and weight objectives alongside glycemic control .

Shift toward non-insulin therapies

GLP-1 and dual GIP/GLP-1 therapies change intensification decisions because they address glycemia while also affecting weight and, for selected agents, cardiorenal risk. ADA guidance directs clinicians to consider these attributes when selecting or intensifying therapy, rather than treating insulin as the automatic next step after oral agents . This increases the strategic value of products that can demonstrate outcome benefits in addition to glucose lowering.

DPP-4 inhibitors participate differently in this shift. Their oral administration and low hypoglycemia risk preserve a role for patients who do not tolerate GLP-1 therapies or decline injections, but their cardiovascular evidence is largely safety rather than superiority ^{[6]National Center for Biotechnology Information, *Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin*. pmc.ncbi.nlm.nih.gov}. As a result, the two classes serve different clinical and pricing positions rather than interchangeable demand pools.

Advancements in drug delivery technologies

Oral semaglutide demonstrated that a peptide incretin can be delivered through the stomach using SNAC, which locally protects semaglutide and supports transcellular absorption ^{[7]Science Translational Medicine, *Transcellular Stomach Absorption of a Derivatized Glucagon-like Peptide-1 Receptor Agonist*. science.org} . This formulation approach matters commercially because it opens an oral route for a class historically associated with injections.

The December 2025 U.S. approval of once-daily oral Wegovy for chronic weight management extends that delivery logic into obesity treatment . Longer dosing intervals and simpler devices may reduce administration friction, but the real commercial test is whether payers recognize sufficient value to cover the additional population that oral products can reach.

Cardiovascular and weight management benefits

Clinical outcomes evidence makes GLP-1 therapies commercially distinct from legacy glucose-lowering products. A 2025 meta-analysis found reductions in major cardiovascular outcomes and mortality across GLP-1 trials , while the SOUL trial showed cardiovascular benefit with oral semaglutide in high-risk type 2 diabetes . These results support treatment pathways that are not contingent solely on inadequate glycemic control.

The obesity opportunity adds scale but also introduces reimbursement risk. WHO estimates that more than one billion people were living with obesity in 2022 . Tirzepatide's three-year SURMOUNT-1 results, including sustained weight loss and lower progression to type 2 diabetes in participants with obesity and prediabetes, illustrate why manufacturers are pursuing broader metabolic indications .

Key Restraints

High treatment costs

Cost is a retention problem as well as an initiation problem. KFF reported that U.S. list prices were approximately USD 935 per month for Ozempic and USD 1,349 for Wegovy, and that 54% of GLP-1 users found the cost difficult to afford . Marketplace coverage also differs sharply by label: KFF found that 82% of plans covered Ozempic, compared with 1% covering Wegovy .

For DPP-4 therapies, generic entry improves access but erodes branded economics. Merck reported that Januvia and Janumet revenue fell from USD 4.51 billion in 2022 to USD 2.27 billion in 2024 amid generic competition outside the U.S. and other pressures ^{[8]Merck & Co., Inc., *Annual Report on Form 10-K, Fiscal Year 2024*. sec.gov}. The market consequently faces a persistent trade-off between broader lower-cost volume and the pricing needed to sustain originator revenues.

Adverse effects and contraindications

Gastrointestinal intolerance constrains persistence in GLP-1 treatment. A systematic review reported discontinuation due to adverse events in 6.5% of GLP-1 users in randomized trials, versus 3.6% with placebo ^{[9]Journal of Clinical Investigation, *Adverse Effects of GLP-1 Receptor Agonists as Glucose-Lowering Agents*. jci.org}. Nausea, vomiting, and diarrhea are most prominent during dose escalation, making titration support part of the effective care model rather than a peripheral service , ^{[10]ScienceDirect, *Weight Loss Outcomes, Tolerability, Side Effects, and Risks of GLP-1 Receptor Agonists*. sciencedirect.com}.

Patient selection also limits use. Product warnings and the pharmacological effect on gastric emptying require clinicians to manage relevant risks around endocrine history, pancreatitis, and procedures . These constraints create room for DPP-4 inhibitors in selected patients even as GLP-1 products command more of the growth and outcome-driven prescribing.

Incretin-based Drugs Market Segment Analysis

By Drug Type

GLP-1 Receptor Agonists

GLP-1 receptor agonists generated USD 25.7 billion in 2025 and accounted for 65.1% of market revenue . Their direct receptor activity produces glucose-dependent insulin secretion, lower glucagon activity, delayed gastric emptying, and appetite effects, making the class relevant across diabetes and obesity treatment . Revenue is concentrated in semaglutide and tirzepatide franchises: Novo Nordisk reported 2024 sales of more than DKK 120 billion for Ozempic and DKK 58.2 billion for Wegovy, while Lilly reported USD 11.54 billion for Mounjaro and USD 4.93 billion for Zepbound.

That concentration is commercially productive but exposes the segment to supply, reimbursement, and lifecycle risks around a limited number of products. Tirzepatide's differentiated dual agonism, including its trial evidence in obesity and prediabetes, supports continued indication expansion .

DPP-4 Inhibitors

DPP-4 inhibitors represented the remaining 34.9% of 2025 revenue . By preventing incretin degradation, they provide an oral, glucose-dependent mechanism with a lower hypoglycemia burden ^{[11]European Medicines Agency, *Vipidia (Alogliptin) Product Information*. ema.europa.eu}. Their strategic role is increasingly defined by affordability, established primary-care use, and suitability for patients unable to use GLP-1 therapies rather than by the outcome-premium that supports GLP-1 pricing.

Sitagliptin's patent transition illustrates the shift. Merck's reported decline in Januvia/Janumet revenue shows how generic substitution can widen access while compressing originator revenue . Linagliptin retains a clinical distinction because it does not require dose adjustment across stages of renal impairment .

By Route of Administration

Oral

Oral therapies represented 76.7% of 2025 revenue, or approximately USD 30.2 billion . The share reflects the established oral DPP-4 base as well as oral semaglutide. SNAC-enabled semaglutide established a proof point for oral delivery of a GLP-1 peptide , and oral Wegovy brings this route into chronic weight management .

Oral expansion does not eliminate execution constraints. Peptide formulations may retain administration requirements that differ from conventional tablets, while reimbursement decisions still depend on the indication and demonstrated outcomes. Nevertheless, oral availability can broaden the prescriber and patient pool where injection aversion is the decisive barrier.

Injectable

Injectables represented approximately 23.3% of 2025 revenue , but contain many of the market's highest-value GLP-1 franchises. Once-weekly administration and pen devices have reduced the burden relative to earlier frequent-injection regimens. Teva's August 2025 launch of generic liraglutide for weight loss signals that price competition is beginning to reach injectable obesity treatment .

By Indication

Type 2 Diabetes Mellitus

Type 2 diabetes mellitus generated USD 28.1 billion, or 71.2%, of 2025 revenue . It remains the foundational indication because treatment infrastructure, prescribing familiarity, and coverage are most developed for diabetes-labelled products. The contrast in Marketplace coverage between Ozempic and Wegovy shows how label-specific reimbursement can influence commercial mix even for related molecules .

Obesity and Weight Management

Obesity and weight management generated about USD 6.5 billion, or 16.4%, of 2025 revenue . The segment's growth case rests on a large disease burden and on the ability of GLP-1 and dual agonists to produce clinically meaningful weight loss. It remains more exposed than diabetes to coverage exclusions, meaning growth depends on conversion of clinical interest into reimbursed access rather than patient demand alone .

Other Metabolic Disorders

Other metabolic disorders accounted for approximately 12.4% of 2025 revenue . These uses are an indication-development frontier rather than a settled revenue pool. In SYNERGY-NASH, tirzepatide produced dose-dependent resolution of metabolic dysfunction-associated steatohepatitis without worsening fibrosis in more participants than placebo . Such evidence can support future development, but commercial uptake remains contingent on regulatory labeling and payer recognition.

By Distribution Channel

Hospital Pharmacies

Hospital pharmacies generated USD 20.1 billion in 2025 revenue . Their role reflects specialist-led initiation, formulary control, and the management of complex cardiometabolic patients. For manufacturers, hospital access is therefore tied to clinical evidence, contracting capability, and treatment-pathway integration.

Retail Pharmacies

Retail pharmacies held 16.8% of 2025 revenue . They remain central to repeat dispensing for established diabetes therapies, particularly oral DPP-4 products. Their economics are more exposed to generic substitution and to supply disruptions in high-demand branded GLP-1 products than hospital channels.

E-commerce

E-commerce represented approximately 31.9% of revenue in 2025 . Lilly's 2024 agreements with Amazon Pharmacy and Ro demonstrate how direct-to-patient pathways can supplement conventional dispensing for obesity products . These channels can reduce friction for self-pay patients, but their long-term value depends on compliant dispensing, supply stability, and sustainable pricing rather than digital acquisition alone.

Incretin-based Drugs Market Regional Analysis

North America

North America accounted for 45.7% of global revenue in 2025 . The region combines high branded prices, broad specialist capacity, and rapid translation of clinical guidance into prescribing. The same factors create an access divide: high list prices and uneven obesity coverage limit the proportion of clinically eligible patients who can sustain treatment.

United States

The U.S. is the region's pricing and launch center. Lilly reported USD 11.54 billion in 2024 Mounjaro revenue and USD 4.93 billion in Zepbound revenue , while Novo Nordisk reported more than DKK 120 billion in Ozempic sales and DKK 58.2 billion in Wegovy sales globally . The commercial opportunity is large, but payer design makes the diabetes and obesity markets materially different even where the underlying incretin mechanism overlaps.

Canada

Canada's opportunity is shaped more by provincial formulary decisions than by U.S.-style list-price realization. This favors products that can meet restricted access criteria and creates a slower, more managed adoption path for high-cost GLP-1 therapies.

Europe

Europe generated USD 8.1 billion in 2025, or 20.6% of global revenue . Regulated pricing moderates revenue per treated patient relative to the U.S., but established public reimbursement can support broad diabetes access. The commercial task is to demonstrate enough incremental clinical value to secure favorable health-technology and reimbursement decisions.

Germany

Germany's benefit-assessment and statutory-insurance environment makes comparative clinical value central to access. Lower prices than in the U.S. can support broader treatment volume, but they also limit the revenue upside of premium GLP-1 products.

United Kingdom

In the United Kingdom, obesity treatment is particularly constrained by the capacity and budget of specialist weight-management services. This places implementation capacity alongside drug efficacy as a determinant of uptake.

France, Spain, Italy, Netherlands

Across these markets, established diabetes reimbursement supports DPP-4 and GLP-1 use within defined treatment pathways. Generic DPP-4 availability provides a lower-cost option, while GLP-1 expansion depends on national coverage decisions for obesity and cardiovascular-risk populations.

Asia Pacific

Asia Pacific held 22.6% of 2025 revenue and is projected to grow at about 6.7% annually through 2035 . The region's growth rests on the scale of diabetes burden: the NCD Risk Factor Collaboration estimated 212 million adults with diabetes in India and 148 million in China in 2022 ^{[12]NCD Risk Factor Collaboration, *Worldwide Trends in Diabetes Prevalence and Treatment from 1990 to 2022*. researchonline.lshtm.ac.uk}. Price sensitivity and reimbursement development will determine whether this epidemiological scale converts into branded GLP-1 revenue or predominantly generic, oral therapy volume.

China

China combines a large diabetes burden with strong pressure on drug prices. Volume-based procurement and local competition can favor affordable oral therapies, while new domestic incretin development increases the prospect of a more locally competitive GLP-1 market. This makes China a volume-led opportunity whose value realization depends on pricing discipline and access policy.

Japan

Japan is a mature market in which reimbursement rules and clinical positioning, rather than patient-population expansion, are likely to govern incretin growth. Products that reduce administration burden or demonstrate cardiovascular value may be better positioned than undifferentiated follow-ons.

India

India's large diabetes burden creates substantial potential volume, but limited reimbursement for premium branded therapies makes affordability decisive. Generic DPP-4 products can therefore be commercially important even when GLP-1 clinical demand is rising.

Australia and South Korea

Australia and South Korea are higher-income secondary markets where formulary restrictions and patient co-payments shape GLP-1 access. Their contribution depends on the pace at which coverage extends from diabetes into obesity treatment.

Latin America

Latin America represented 7.1% of 2025 revenue . High out-of-pocket exposure constrains premium GLP-1 use, making generic DPP-4 products an important access route. Growth will be uneven because private insurance depth, currency conditions, and public procurement differ materially across countries.

Brazil and Mexico

Brazil and Mexico are the region's principal commercial markets. Their dual public-private systems favor branded GLP-1 uptake in private care while public channels remain more sensitive to generic cost and formulary discipline.

Argentina

Argentina's currency and import-cost volatility add a supply and affordability risk that is less pronounced in larger regional markets. Specialty and private channels are likely to remain important for premium therapies.

Middle East and Africa

The Middle East and Africa represented about 4.0% of global revenue in 2025 . Market value is concentrated in better-funded Gulf systems, while limited public reimbursement and lower healthcare spending restrict broad branded use elsewhere.

Saudi Arabia and UAE

Saudi Arabia and the UAE offer the region's strongest commercial conditions because private care capacity and purchasing power support specialty diabetes and obesity treatment. Access is likely to widen first in these systems rather than uniformly across the region.

South Africa

South Africa has comparatively developed pharmaceutical distribution in sub-Saharan Africa, but branded GLP-1 access remains concentrated among privately insured patients. Affordability will continue to determine whether latent metabolic-disease demand becomes treated demand.

Incretin-based Drugs Market Share & Competitive Landscape

The market combines high concentration in premium GLP-1 therapy with broader competition in DPP-4 products. Novo Nordisk, Eli Lilly, Takeda, Merck, and Sanofi collectively held approximately 35% of global market share in 2025 . Competitive advantage increasingly depends on clinical differentiation, delivery format, access capabilities, and lifecycle management rather than on diabetes positioning alone.

AstraZeneca is developing metabolic assets including AZD5004, an oral GLP-1 receptor agonist, alongside other obesity pipeline programs ^{[13]AstraZeneca, *Development Pipeline 2024*. astrazeneca.com}. Its cardiovascular and renal franchise provides a logical clinical adjacency, but the company must establish differentiation in a field already led by scaled GLP-1 incumbents.

Boehringer Ingelheim retains a DPP-4 position through linagliptin. The product's lack of renal dose-adjustment requirement gives it a targeted role in type 2 diabetes with renal impairment , while cardiovascular outcome trials established safety rather than the superiority profile associated with leading GLP-1 therapies .

Eli Lilly and Company is a leading GLP-1 competitor through tirzepatide. Mounjaro and Zepbound delivered USD 11.54 billion and USD 4.93 billion, respectively, in 2024 . Its next strategic test is translating dual-agonist leadership into broader formats and indications while managing capacity and payer access.

GlaxoSmithKline is a historical GLP-1 participant following the discontinuation of albiglutide. The HARMONY Outcomes result remains part of the class cardiovascular evidence base, but GSK's disclosed pipeline does not establish a current marketed incretin position ^{[14]GSK, *Positive Results from HARMONY Outcomes Study of Albiglutide Published in The Lancet*. gsk.com} .

Merck faces a managed decline in sitagliptin as generic competition erodes Januvia and Janumet. The franchise's 2024 revenue decline underscores the degree to which DPP-4 economics are changing .

Novo Nordisk remains a central GLP-1 leader, with Ozempic and Wegovy generating more than DKK 120 billion and DKK 58.2 billion, respectively, in 2024 . Its oral semaglutide portfolio and oral Wegovy approval extend its ability to compete across diabetes, obesity, and route-of-administration choices .

Pfizer re-entered the field through its November 2025 acquisition of Metsera for up to USD 10 billion . The transaction supplies a pipeline centered on differentiated dosing and oral options after Pfizer discontinued internal oral GLP-1 candidates.

Sanofi participates through Soliqua, which combines insulin glargine with lixisenatide for type 2 diabetes. Its position is most relevant where a fixed combination can simplify intensification, rather than in direct competition for standalone high-dose obesity GLP-1 share.

Takeda Pharmaceutical Company markets alogliptin, a selective DPP-4 inhibitor for adults with type 2 diabetes . Its established-franchise posture illustrates the contrast between DPP-4 maintenance economics and the R&D intensity of the GLP-1 pipeline race.

Teva Pharmaceuticals provides the key generic disruption case. Its August 2025 U.S. launch of generic liraglutide for weight loss brought generic competition into the GLP-1 obesity category , creating an access-expanding but price-compressing precedent for later patent expiries.

Recent Industry Developments

• August 2025 - Teva Pharmaceuticals: Teva announced FDA approval and launch of generic liraglutide injection for weight loss, indicated for adults with obesity or overweight with a weight-related comorbidity and certain pediatric patients .
• November 2025 - Pfizer/Metsera: Pfizer completed its acquisition of Metsera for up to USD 10 billion, adding metabolic pipeline assets including a once-monthly injectable GLP-1 candidate .
• December 2025 - Novo Nordisk/FDA: Novo Nordisk announced FDA approval of once-daily oral Wegovy for chronic weight management .
• December 2024 - Eli Lilly/FDA: The FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity .
• November 2024 - Eli Lilly/SURMOUNT-1: Lilly reported three-year SURMOUNT-1 results showing lower progression to type 2 diabetes in adults with obesity and prediabetes treated with tirzepatide .
• 2025 - SOUL trial: The New England Journal of Medicine published the SOUL trial, reporting cardiovascular benefit with oral semaglutide in high-risk type 2 diabetes .
• March and December 2024 - Lilly direct distribution: Lilly partnered with Amazon Pharmacy and later Ro to expand direct-to-patient distribution for relevant products.